

## Literatura ACTA MEDICINAE 10–11/2018 Onkologie | Hematoonkologie

- 3 **Imunoterapie nemalobuněčných karcinomů plic – současný stav a budoucnost**  
prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN, Praha
- 3 **Léčba karcinomu plic aktuálně a výhledy**  
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha
- 4 **Poslední výsledky analýzy dat klinické studie ALEX (data cut-off 12/2017)**  
MUDr. Daniel Krejčí Klinika pneumologie a hrudní chirurgie, Nemocnice na Bulovce, Praha
- 4 **Studie APHINITY: Adjuvantní léčba zachraňuje životy**  
prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK Plzeň
- 4 **Dočkají se naše nemocné? Léčba pokročilého karcinomu prsu inhibitory CDK4/6**  
MUDr. Miloš Holánek Klinika komplexní onkologické péče, MOÚ, Brno
- 4 **Pertuzumab v neoadjuvantní léčbě karcinomu prsu**  
MUDr. Markéta Protivánková Interní hematologická a onkologická klinika, LF MU a FN Brno
- 4 **Je čas na změnu algoritmu léčby pokročilého karcinomu ledviny?**  
prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK Plzeň
- 5 **Pacientka s pokročilým gastrointestinálním stromálním nádorem léčeným sunitinibem – kazuistika**  
MUDr. Zdeněk Linke Onkologická klinika 2. LF UK a FN v Motole, Praha
- 5 **Levá a pravá – význam lokalizace primárního nádoru u kolorektálního karcinomu**  
MUDr. Michal Vočka | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika, VFN a 1. LF UK, Praha
- 5 **Studie PRECONNECT: Přínos trifluridin/tipiracilu u pacientů s metastatickým kolorektálním karcinomem**  
MUDr. Beatrix Bencsiková, Ph.D. Klinika komplexní onkologické péče, Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno
- 5 **Teysuno v léčbě metastatického karcinomu žaludku**  
MUDr. Radka Obermannová, Ph.D. Klinika komplexní onkologické péče, MOÚ a MU, Brno
- 5 **Ramucirumab – cílený zásah jaterních metastáz karcinomu gastroezofageální junkce – kazuistika**  
MUDr. Sabina Svobodová | MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u sv. Anny v Brně  
MUDr. Adam Peštál, Ph.D. I. chirurgická klinika, FN u sv. Anny v Brně  
MUDr. Igor Suškevič Klinika zobrazovacích metod, FN u sv. Anny v Brně
- 6 **Monoterapie, nebo kombinovaná léčba inhibitory kontrolních bodů imunity v první linii léčby pacientů s metastazujícím melanomem?**  
MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha
- 6 **Léčba generalizovaného maligního melanomu kombinací BRAF inhibitoru dabrafenibu s MEK inhibitorem trametinibem – kazuistika**  
MUDr. Michaela Fridrichová Ústav radiační onkologie Nemocnice Na Bulovce, Praha
- 6 **Pacient s mnohočetným recidivujícím bazocelulárním karcinomem – kazuistika**  
MUDr. Renata Emmerová Komplexní onkologické centrum, KN Liberec, a. s., Liberec
- 6 **Lenvatinib – nově dostupná možnost léčby radiojod refrakterního diferencovaného karcinomu štítné žlázy**  
MUDr. Hana Švébišová, Ph.D. Onkologická klinika a LF UP, Olomouc
- 6 **Kam směřuje léčba chronické myeloidní leukemie inhibitory tyrosinové kinázy?**  
MUDr. Hana Klamová, Ph.D. Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie 1. LF UK, Praha
- 7 **Hodgkinův lymfom u starších nemocných**  
MUDr. Alice Sýkorová, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové  
MUDr. Heidi Móciková, Ph.D. Oddělení klinické hematologie, FN Královské Vinohrady a 3. LF UK, Praha
- 8 **Můžeme upravit intenzitu úvodní léčby u Hodgkinova lymfomu podle výsledku průběžného PET?**  
doc. MUDr. Vít Procházka, Ph.D. | MUDr. Marie Lukášová Hemato-onkologická klinika Fakultní nemocnice Olomouc  
MUDr. Lenka Henzlová, Ph.D. Klinika nukleární medicíny Fakultní nemocnice Olomouc  
prof. MUDr. Tomáš Papajík, CSc. Hemato-onkologická klinika Fakultní nemocnice Olomouc

- 8 **Primární lymfom centrální nervové soustavy – kam kráčíš?**  
MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FNKV a 3. LF UK, Praha
- 8 **Úspěšná léčba obinutuzumabem s chlorambucilem u staršího pacienta s masivní lymfadenopatií – kazuistika**  
MUDr. Martin Špaček, Ph.D. I. interní klinika – klinika hematologie 1. LF UK a VFN, Praha
- 9 **Úspěšná léčba venetoklaxem u pacientky s abruptivním relapsem předléčené relabující/refrakterní chronické lymfocytární leukemie po selhání terapie idelalisibem a ibrutinibem – kazuistika**  
MUDr. Peter Turcsányi, Ph.D. | MUDr. Renata Urbanová, Ph.D. | prof. MUDr. Tomáš Papajík CSc.  
Hemato-onkologická klinika FN Olomouc
- 9 **Aktuální léčba relabované a refrakterní chronické lymfocytární leukemie – kazuistika**  
MUDr. Martin Šimkovič, Ph.D. IV. interní hematologická klinika, FN Hradec Králové
- 9 **Management lymfomů v těhotenství**  
MUDr. Jan Kořen I. interní klinika – klinika hematologie, 1. LF UK a VFN, Praha
- 9 **Příznivý vliv dasatinibu na kompenzaci diabetu u pacienta s chronickou myeloidní leukemií – kazuistika**  
MUDr. Petra Bělohávková, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové
- 10 **Nová doporučení pro léčbu chronické lymfocytární leukemie a ibrutinib**  
MUDr. Jakub Trizuljak | prof. MUDr. Michael Doubek, Ph.D. Interní hematologická a onkologická klinika, LF a FN Brno, Středoevropský technologický institut (CEITEC) Masarykovy univerzity, Brno

# Imunoterapie nemalobuněčných karcinomů plic – současný stav a budoucnost

prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN, Praha

- 1 **Brahmer, J. – Reckamp, K. L. – Baas, P., et al.**: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*, 2015, 373, s. 123–135.
- 2 **Borghaei, H. – Paz-Ares, L. – Horn, L., et al.**: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med*, 2015, 373, s. 1627–1639.
- 3 **Herbst, R. S. – Baas, P. – Kim, D. W., et al.**: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*, 2016, 387, s. 1540–1550.
- 4 **Rittmeyer, A. – Barlesi, F. – Waterkamp, D., et al.**: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet*, 2017, 389, s. 255–265.
- 5 **Kim, J. M. – Chen, D. S.**: Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). *An Oncol*, 2016, 27, s. 1492–1504.
- 6 **Chen, D. S. – Mellam, I.**: Elements of cancer immunity and the cancer-immune set point. *Nature*, 2017, 541, s. 321–330.
- 7 **Hegde, P. S. – Karanikas, V. – Evers, S.**: The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. *Clin Cancer Res*, 2016, 22, s. 1865–1874.
- 8 **Gandhi, L. – Rodríguez-Abreu, D. – Gadgeel, S., et al.**: Keynote-189 investigators: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med*, 2018, 378, s. 2078–2092, doi: 10.1056/NEJMoa1801005.
- 9 **Socinsky, M. A. – Jotte, R. M. – Frederico Cappuzzo, M. D., et al.**: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med*, 2018, 378, s. 2288–2301.
- 10 **Hellmann, M. D. – Ciuleanu, T. E. – Pluzanski, A., et al.**: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. *N Engl J Med*, 2018, 378, s. 2093–2104.
- 11 **Meloy, B.**: Current treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. Mini review article. *Front Oncol*, 20. 3. 2017, <https://doi.org/10.3389/fonc.2017.00038>.
- 12 **Reck, M. – Rodríguez-Abreu, D. – Robinson, A. G., et al.**: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med*, 2016, 375, s. 1823–1833.
- 13 **Lopes, G. – Wu, Y. – Kudaba, I., et al.**: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS)  $\geq$  1%: Open-label, phase 3 KEYNOTE-042 study. *J Clin Oncol*, 2018, 36, suppl., abstrakt LBA4.
- 14 **Paz-Ares, L. – Luft, A. – Tafreshi, A., et al.**: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). *J Clin Oncol*, suppl., 2018, [http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15\\_suppl.105](http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.105).
- 15 **Carbone, D. P. – Reck, M. – Paz-Ares, L., et al.**: First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. *N Engl J Med*, 2017, 376, s. 2415–2426.
- 16 **Borghaei, H. – Paz-Ares, L. – Horn, L., et al.**: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med*, 2015, 373, s. 1627, doi: 10.1056/NEJMoa1507643; *J Clin Oncol*, suppl., 2018.

## Léčba karcinomu plic aktuálně a výhledy

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha

- 1 **Scagliotti, G. V., et al.**: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol*, 2008, 26, s. 3543–3551.
- 2 **Yang, J. C., et al.**: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA study Phase II extension cohort. Abstrakt 943, přednáška. Prezentováno na 16<sup>th</sup> World Conference on Lung Cancer, 6.–9. 9. 2015, Denver, CO.
- 3 **Mitsudomi, T., et al.**: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 Phase II study. Abstrakt 1406, přednáška. Prezentováno na 16<sup>th</sup> World Conference on Lung Cancer, 6.–9. 9. 2015, Denver, CO.
- 4 **Mok, T. S. – Wu, Y. L. – Ahn, M. J., et al.**: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N Engl J Med*, 2017, 376, s. 629–640.
- 5 **Soria, J. C. – Ohe, Y. – Vansteenkiste, J., et al.**: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med*, 2018, 378, s. 113–125.
- 6 **Vansteenkiste, J. – Reungwetwattana, T. – Nakagawa, K., et al.**: CNS response to osimertinib vs standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA. Prezentováno na European Society of Medical Oncology Asia Congress, 17.–19. 11. 2017, Singapur, abstrakt LBA5.
- 7 **Thatcher, N. – Hirsch, F. R. – Luft, A. V., et al.**: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQIRE): an open-label, randomised, controlled phase 3 trial. *Lancet Oncology*, 2015, 16, s. 763–774.
- 8 **Soria, J. C. – Tan, D. S. – Chiari, R., et al.**: First-line ceritinib versus platinum based chemotherapy in advanced ALK-rearranged non-small cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *Lancet*, Epub 24. 1. 2017.
- 9 **Shaw, A. T. – Kim, T. M. – Crinò, L., et al.**: Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. *Lancet*, 2017, 18, s. 874–886.
- 10 **Gettinger, S. N. – Bazhenova, L. A. – Langer, C. J., et al.**: Activity and safety of brigatinib in ALK-rearranged non-small cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. *Lancet Oncol*, 2016, 17, s. 1683–1696.
- 11 **Camidge, D. – Tiseo, M. – Ahn, M., et al.**: Brigatinib in crizotinib-refractory ALK+ NSCLC: Central assessment and updates from ALTA, a pivotal randomized phase 2 trial. Prezentováno na 17<sup>th</sup> World Conference on Lung Cancer, prosinec 2016, Vídeň, Rakousko.
- 12 **Solomon, B., et al.**: Phase 2 study of lorlatinib in patients with advanced ALK+ /ROS1+ non-small-cell lung cancer. Prezentováno na International Association for the Study of Lung Cancer (IASLC) 18<sup>th</sup> World Conference on Lung Cancer, 16. 10. 2017, abstrakt #OA 05.06.
- 13 **Novello, S. – Mazières, J. – Oh, I.-J., et al.**: Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. *An Oncol*, mdy121, <https://doi.org/10.1093/annonc/mdy121>.
- 14 **Solange, P. – Ross Camidge, D. – Shaw, A. T., et al.**: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *N Engl J Med*, 2017, 377, s. 829–838.
- 15 **Camidge, D. R., et al.**: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. *J Clin Oncol*, 2018, 36, suppl., abstrakt 9043.
- 16 **Shaw, A. T., et al.**: Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med*, 2014, 371, s. 1963–1971.
- 17 **Ahn, M.-J. – Cho, B. C. – Siena, S., et al.**: Entrectinib in patients with locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). Prezentováno na IASLC 18<sup>th</sup> World Conference on Lung Cancer, 15.–18. 10. 2017, Jokohama, Japonsko, abstrakt 8564.
- 18 **Drilon, A. – De Braid, F. G. – Siena, S., et al.**: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements. Prezentováno na AACR Annual Meeting, 16.–20. 4. 2016, New Orleans, Louisiana, abstrakt CT007.
- 19 **Sandler, A., et al.**: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *NEJM*, 2006, 355, s. 2542–2550.
- 20 **Reck, M. – Kaiser, R. – Mellema, A., et al.**: LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. *Lancet Oncol*, 2014, 15, s. 143–155, doi: 10.1016/S1470-2045(13)70586-2, Epub 9. 1. 2014.
- 21 **Garon, E. B. – Ciuleanu, T. E. – Arrieta, O., et al.**: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. *Lancet*, 2014, 384, s. 665–673.
- 22 **Seto, T. – Kato, T. – Nishio, M., et al.**: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO 25567): an open-label, randomised, multicentre, phase 2 study. *Lancet Oncol*, 2014, 15, s. 1236–1244.
- 23 **Brahmer, J. R. – Rodríguez-Abreu, D. – Robinson, A. G., et al.**: Progression after the next line of therapy (PF2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS)  $\geq$ 50% enrolled in KEYNOTE-024. 2017 ASCO Annual Meeting. *J Clin Oncol*, 2017, 35, suppl., abstrakt 9000.
- 24 **Spigel, D. R., et al.**: A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2015, 33, suppl., abstrakt 8009.
- 25 **Paz-Ares, L. – Horn, L. – Borghaei, H., et al.**: Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2015, 33, suppl., abstrakt LBA109.
- 26 **Horn, L. – Spigel, D. R. – Vokes, E. E., et al.**: Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase iii trials (CheckMate 017 and CheckMate 057). *J Clin Oncol*, 2017, 35, s. 3924–3933.
- 27 **Herbst, R. S. – Kim, D.-W. – Felip, E., et al.**: KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1-positive NSCLC after platinum-based therapy. Prezentováno na ESMO Asia 2015 Congress, Singapur, 18.–21. 12. 2015, LBA3 PR.
- 28 **Rittmeyer, A. – Barlesi, F. – Waterkamp, D., et al.**: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet*, 2017, 389, s. 255–265.
- 29 **Papadimitrakopoulou, V. – Gadgeel, S. M. – Borghaei, H., et al.**: First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G. *J Clin Oncol*, 2017, 35, suppl., s. 9094–9094, DOI: 10.1200/JCO.2017.35.15\_suppl.9094.
- 30 **Gandhi, L. – Rodríguez-Abreu, D. – Gadgeel, S., et al.**: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med*, 2016, 375, s. 1823–1833.
- 31 **Reck, M., et al.**: Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMPOWER150). *An Oncol*, 2017, 28, suppl. 11, 1. 12. 2017, mdx760.002.
- 32 **Socinski, M. A., et al.**: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med*, 2018, 378, s. 2288–2301.
- 33 **Borghaei, H.**: Nivolumab + ipilimumab, nivolumab + chemotherapy, and chemotherapy in chemo-naïve patients with advanced non-small cell lung cancer and < 1 % tumor PD-L1 expression: results from CheckMate 227. Prezentováno na ASCO 2018 Meeting (přednáška).
- 34 **Jotte, R. M. – Cappuzzo, F. – Wynnychenko, I., et al.**: IMPower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. *J Clin Oncol*, 2018, 36, suppl., abstrakt LBA9000.
- 35 **Scott, J. A. – Bendell, J. C. – Tailor, M. H., et al.**: Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. *J Clin Oncol*, 2015, 33, suppl., abstrakt 7503).
- 36 **Hellmann, M. D. – Ciuleanu, T. E. – Pluzanski, A., et al.**: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. *N Engl J Med*, 2018, 378, s. 2093–2104.
- 37 **Scott, J. A. – Villegas, A. – Daniel, D., et al.**: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, November 16, 2017. *N Engl J Med*, 2017, 377, s. 1919–1929.
- 38 **Antonia, S. J. – Villegas, A. – Daniel, D., et al.**: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer [article and supplementary appendix]. *N Engl J Med*, 2017, 377, s. 1919–1929.
- 39 **Hellmann, M. D. – Callahan, M. K. – Awad, M. M., et al.**: Tumor mutation burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small cell lung cancer. *Cancer Cell*, 2018, 33, s. 853–861.
- 40 **Camidge, D. R., et al.**: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. NCT02075840, ASCO 2018. *J Clin Oncol*, 2018, 36, suppl., abstrakt 9043.
- 41 **Brahmer, J., et al.**: Updated analysis of KEYNOTE-024: Pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 TPS  $\geq$ 50%. Prezentováno na WCLC 2017, abstrakt OA17.06. *J Thor Oncol*, 2017, 12, suppl. 2, s. S1793–S1794, <https://doi.org/10.1016/j.jtho.2017.09.431>.
- 42 **Lopes, G. – Wu Y.-L. – Kudaba, I., et al.**: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS)  $\geq$  1%: Open-label, phase 3 KEYNOTE-042 study. Prezentováno na ASCO 2018. *J Clin Oncol*, 2018, 36, suppl., abstrakt LBA4.
- 43 **Paz-Ares, L. G. – Luft, A. – Tafreshi, A., et al.**: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). Prezentováno na ASCO 2018. *J Clin Oncol*, 2018, 36, suppl., abstrakt 105.
- 44 **Socinski, M. A. – Jotte, R. M. – Cappuzzo, F., et al.**: Overall survival (OS) analysis of IMPower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo)  $\pm$  bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. *J Clin Oncol*, 2018, 36, suppl., abstrakt 9002.

# Poslední výsledky analýzy dat klinické studie ALEX (data cut-off 12/2017)

MUDr. Daniel Krejčí Klinika pneumologie a hrudní chirurgie, Nemocnice na Bulovce, Praha

- 1 Skříčková, J. – Kolek, V., et al.: *Základy moderní pneumoonkologie*. Maxdorf Jesenius, 2017, s. 168.
- 2 Rangachari, D. – Yamaguchi, N. – Van der Laan, P. A., et al.: Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. *Lung Cancer*, 2015, s. 88:108–111.
- 3 Peters, S. – Camidge, D. R. – Shaw, A. T., et al.: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *N Engl J Med*, 2017, 377, s. 829–838.
- 4 SPC Alectinib.
- 5 Camidge, D. R. – Peters, S. – Mok, T., et al.: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. ASCO 2018. *J Clin Oncol*, 2018, 36, suppl., abstrakt 9043.
- 6 Novello, S. – Barlesi, F., et al.: Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines. Publikováno 2016. *Ann Oncol*, 2016, 27, suppl. 5, v1–v27.
- 7 www.sukl.cz

## Studie APHINITY: Adjuvantní léčba zachraňuje životy

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK Plzeň

- 1 Minckwitz, G. – Procter, M. – Azambuja, E., et al.: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. *N Engl J Med*, 2017, 377, s. 122–131, doi: 10.1056/NEJMoa1703643, Epub 5. 6. 2017.

## Dočkají se naše nemocné? Léčba pokročilého karcinomu prsu inhibitory CDK4/6

MUDr. Miloš Holánek Klinika komplexní onkologické péče, MOÚ, Brno

- 1 Baselga, J., et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *New Eng J Med*, 2012, 366, s. 520–529.
- 2 Fasching, P. A., et al.: Breast cancer treatment with everolimus and exemestane for ER+ women—results of the 2<sup>nd</sup> interim analysis of the non-interventional trial brawo. *An Oncol*, 2014, 25, suppl. 4, mdu438. 6.
- 3 Finn, R. S., et al.: Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). *Cancer Research*, 2014, 74, suppl., CT101.
- 4 Finn, R. S., et al.: Palbociclib and letrozole in advanced breast cancer. *New Eng J Med*, 2016, 375, s. 1925–1936.
- 5 Cristofanilli, M., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*, 2016, 17, s. 425–439.
- 6 Finn, R. S., et al.: Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontone treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). *J Clin Oncol*, 2017, 35, suppl. 1001, DOI: 10.1200/JCO.2017.35.15\_suppl.1001.
- 7 Hortobagyi, G. N., et al.: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *New Eng J Med*, 2016, 375, s. 1738–1748.
- 8 Hortobagyi, G. N., et al.: Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC). *Ann Oncol*, 2018, 29, s. 1541–1547, doi: 10.1093/annonc/mdy155.
- 9 Slamon, D. J., et al.: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. *J Clin Oncol*, 2018, JCO2018789909, doi: 10.1200/JCO.2018.78.9909.
- 10 Didkter, M. N., et al.: MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. *J Clin Oncol*, 2016, 34, suppl. 510, DOI: 10.1200/JCO.2016.34.15\_suppl.510.
- 11 Goetz, M. P., et al.: MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol*, 2017, 35, s. 3638–3646, doi: 10.1200/JCO.2017.75.6155, Epub 2. 10. 2017.
- 12 Sledge, J. R. – George, W., et al.: MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol*, 2017, 35, s. 2875–2884.

## Pertuzumab v neoadjuvantní léčbě karcinomu prsu

MUDr. Markéta Protivánková Interní hematologická a onkologická klinika, LF MU a FN Brno

- 1 Teshome, M. – Hunt, K. K.: Neoadjuvant therapy in the treatment of breast cancer. *Surg Oncol Clin N Am*, 2014, 23, s. 505–523.
- 2 Vyzula, R., et al.: *Modrá kniha ČOS ČLS JEP*. Aktualizace: 24. Brno, Masarykův onkologický ústav.
- 3 Perez, E. A. – Romond, E. H. – Suman, V. J., et al.: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. *J Clin Oncol*, 2014, 32, s. 3744–3752.
- 4 Gianni, L. – Eiermann, W. – Semiglazov, V., et al.: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer: a randomised controlled superiority trial with a parallel HER2-negative cohort (the NOAH trial). *Lancet*, 2010, 375, s. 377–384.
- 5 Gianni, L. – Eiermann, W. – Semiglazov, V., et al.: Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet Oncol*, 2014, 15, s. 640–647.
- 6 Fendly, B. M. – Winget, M. – Hudziak, R. M., et al.: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. *Cancer Res*, 1990, 50, s. 1550–1558.
- 7 Gianni, L. – Pienkowski, T. – Im, Y. H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2012, 13, s. 25–32.
- 8 Gianni, L. – Pienkowski, T. – Im, Y. H., et al.: 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. *Lancet Oncol*, 2016, 17, s. 791–800.
- 9 Schneeweiss, A. – Chia, S. – Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). *Ann Oncol*, 2013, 24, s. 2278–2284.
- 10 Untch, M. – Jackisch, C. H. – Schneeweiss, A., et al.: Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69). *Lancet Oncol*, 2016, 17, s. 345–356.
- 11 Schneeweiss, A. – Chia, S. – Hickish, T., et al.: Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. *Lancet Oncol*, 2016, 17, s. 791–800.
- 12 Swain, S. V. – Ewer, M. S. – Viale, G., et al.: Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. *An Oncol*, 2018, 29, s. 646–653.
- 13 Baselga, J. – Swain, S. M.: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. *Nat Rev Cancer*, 2009, 9, s. 463–475.
- 14 Gianni, L. – Pienkowski, T. – Im, Y. H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2012, 13, s. 25–32.
- 15 Schneeweiss, A. – Chia, S. – Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). *Ann Oncol*, 2013, 24, s. 2278–2284.
- 16 A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer. NCT02132949. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT02132949>, vyhledáno 9. 6. 2015, ClinicalTrials.gov Identifier: NCT02132949.

## Je čas na změnu algoritmu léčby pokročilého karcinomu ledviny?

prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK Plzeň

- 1 Motzer, R. J. – Tannir, N. M. – McDermott, D. F., et al.: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *NEJM*, 21. 3. 2018, dostupné z NEJM.org.
- 2 Escudier, B. – Sharma, P. – McDermott, D. F., et al.: CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. *Eur Urol*, 2017, 72, s. 962–971, doi: 10.1016/j.eururo.2017.02.010, Epub 3. 3. 2017.

# Pacientka s pokročilým gastrointestinálním stromálním nádorem léčeným sunitinibem – kazuistika

MUDr. Zdeněk Linke Onkologická klinika 2. LF UK a FN v Motole, Praha

- 1 Heindrich, M. C. – Maki, R. G. – Corless, C. L., et al.: Sunitinib response in imatinib-resistant GIST correlates with KIT and PDGFR mutation status. *J Clin Oncol*, 2006, 24, s. 9502.
- 2 Demetri, G. D. – van Oosterom, A. T., et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet*, 2006, s. 6736–6746.

# Levá a pravá – význam lokalizace primárního nádoru u kolorektálního karcinomu

MUDr. Michal Vočka | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika, VFN a 1. LF UK, Praha

- 1 Hutchins, G. – Southward, K. – Handley, K., et al.: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. *J Clin Oncol*, 2011, 29, s. 1261–1270.
- 2 Henrichsen-Schnack, T. – Ladelund, S. – Nilbert, M.: The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. *Acta Oncol*, 2014, 53, s. 852–864.
- 3 Petrelli, F. – Tomasello, G. – Borgonovo, K., et al.: Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. *JAMA Oncology*, 2017, 3, s. 211–219.
- 4 Dienstmann, R.: Tumor side as model of integrative molecular classification of colorectal cancer. *Clin Cancer Res*, 2018, 24, s. 989–990.
- 5 Shimada, Y. – Kameyama, H. – Nagahashi, M., et al.: Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. *Oncotarget*, 2017, 8, s. 93567–93579.
- 6 Salem, M. E. – Weinberg, B. A. – Xiu, J., et al.: Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. *Oncotarget*, 2017, 8, s. 86356–86368.
- 7 Guinney, J. – Dienstmann, R. – Wang, X., et al.: The consensus molecular subtypes of colorectal cancer. *Nat Med*, 2015, 21, s. 1350–1356.
- 8 Pugh, S. A. – Shinkins, B. – Fuller, A., et al.: Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postrecurrence survival: data from the FACTS randomized controlled trial. *Ann Surg*, 2016, 263, s. 1143–1147.
- 9 Arnold, D. – Lueza, B. – Douillard, J. Y., et al.: Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. *Med Oncol*, 2017, 28, s. 1713–1729.
- 10 Holch, J. W. – Ricard, I. – Stintzing, S., et al.: The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. *Eur J Cancer*, 2017, 70, s. 87–98.
- 11 Tejpar, S. – Stintzing, S. – Ciardiello, F., et al.: Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. *JAMA Oncol*, 2017, 3, s. 194–201.
- 12 Hibberd, A. A. – Lyra, A. – Ouwehand, A. C., et al.: Intestinal microbiota altered in patients with colon cancer and modified by probiotic intervention. *BMJ open Gastroenterol*, 2017, 4, s. e000145.
- 13 Mima, K. – Nishihara, R. – Qian, Z. R., et al.: Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. *Gut*, 2016, 65, s. 1973–1980.
- 14 Lee, G. H. – Malietz, G. – Askari, A., et al.: Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review. *Eur J Surg Oncol*, 2015, 41, s. 300–308.

# Studie PRECONNECT: Přínos trifluridin/tipiracilu u pacientů s metastatickým kolorektálním karcinomem

MUDr. Beatrix Bencsiková, Ph.D. Klinika komplexní onkologické péče, Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno

- 1 Falcone, A. – Andre, T. – Edeline, J., et al.: Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase 3b, international, open-label, early-access PRECONNECT study. Abstract O-013. Poster prezentován na ESMO 20<sup>th</sup> World Congress on Gastrointestinal Cancer, 20–23. 6. 2018, Barcelona, Španělsko.
- 2 Emura, T. – Nakagawa, F. – Fujioka, A., et al.: An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. *Int J Mol Med*, 2004, 13, s. 249–255.
- 3 Mayer, R. J. – Van Cutsem, E. – Falcone, A., et al.: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med*, 2015, 372, s. 1909–1919.
- 4 Yoshino, T. – Mizunuma, N. – Yamazaki, K., et al.: TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. *Lancet Oncol*, 2012, 13, s. 993–1001.

# Teysuno v léčbě metastatického karcinomu žaludku

MUDr. Radka Obermannová, Ph.D. Klinika komplexní onkologické péče, MOÚ a MU, Brno

- 1 Lordick, F. – Lorenzen, S. – Yamada, Y., et al.: Optimal chemotherapy for advanced gastric cancer: is there a global consensus? *Gastric Cancer*, 2014, 17, s. 213–225.
- 2 Bang, Y. J. – Van Cutsem, E. – Feyereislova, A., et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet*, 2010, 376, s. 687–697.
- 3 Fuchs, C. S. – Tomasek, J. – Yong, C. J., et al.: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*, 2014, 383, s. 31–39.
- 4 Wilke, H. – Muro, K. – Van Cutsem, E., et al.: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol*, 2014, 15, s. 1224–1235.
- 5 Okines, A. F. C. – McCloud, P. – Kang, Y., et al.: Meta-analysis of the REAL-2 and ML17032 trials comparing capecitabine with 5-FU in advanced oesophageal gastric cancer. *An Oncol*, 2008, 19, viii169, abstrakt 513PD.
- 6 Ajani, J. A. – Rodriguez, W. – Bodoky, G., et al.: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS Trial. *J Clin Oncol*, 2010, 28, s. 1547–1553.
- 7 Nakamura, M. – Yamada, Y. – Muro, K., et al.: The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitor fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. *Future Oncol*, 2015, 11, s. 1471–1478, doi: 10.2217/fon.15.59.

# Ramucirumab – cílený zásah jaterních metastáz karcinomu gastroezofageální junkce – kazuistika

MUDr. Sabina Svobodová | MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u sv. Anny v Brně

MUDr. Adam Pešťál, Ph.D. I. chirurgická klinika, FN u sv. Anny v Brně

MUDr. Igor Suškevič Klinika zobrazovacích metod, FN u sv. Anny v Brně

- 1 Wilke, H. – Muro, K. – Van Cutsem, E., et al.: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol*, 2014, 15, s. 1224–1235.
- 2 Fuchs, C. S. – Tomasek, J. – Yong, C. J., et al.: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet Oncol*, 2014, 383, s. 31–39.
- 3 Shitara, K., et al.: Effect of post-discontinuation therapy on survival in metastatic gastric-gastroesophageal junction adenocarcinoma patients from the RAINFALL trial: An exploratory analysis. ASCO, Chicago, červen 2018, poster 4044.
- 4 Bang, Y. J. – Van Cutsem, E. – Feyereislova, A., et al.: Trastuzumab

- in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet*, 2010, 376, s. 687–697.
- 5 Staněk, L. – Tesařová, P. – Gürlich, R., et al.: *Molekulární onkologie v kazuistikách*. Current Media, Praha, 2017.
- 6 Klener, P. – Klener, P. jr.: *Nová protinádorová léčiva a léčebné strategie v onkologii*. Grada, 2010.
- 7 Kolektiv autorů: *Klinická onkologie*. 2017, 30, suppl. 3: Advances in immunotherapy.
- 8 NCCN Clinical Guidelines in Oncology verze 2.2018, dostupné z: [www.nccn.org](http://www.nccn.org).
- 9 *Modrá kniha České onkologické společnosti*, 24. aktualizace, platnost od 1. 3. 2018.
- 10 Souhrn údajů o přípravku Cynamza (ramucirumab ), Eli Lilly 1/2016, dostupné z: [www.ema.europa.eu](http://www.ema.europa.eu).

## Monoterapie, nebo kombinovaná léčba inhibitory kontrolních bodů imunity v první linii léčby pacientů s metastazujícím melanomem?

MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha

- 1 De Coana, Y. P. – Wolodarski, M. – Poschke, I., et al.: Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. *Oncotarget*, 2017, 8, s. 21539–21553.
- 2 Weber, J. S. – Gibney, G. – Sullivan, R. J., et al.: Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. *Lancet Oncol*, 2016, 17, s. 943–955.
- 3 Hodi, F. S. – Chesney, J. – Pavlick, A. C., et al.: Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma. *Lancet Oncol*, 2016, 17, s. 1558–1568.
- 4 Wolchok, J. D. – Chiarion-Sileni, V. – Gonzales, R., et al.: Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med*, 2017, 377, s. 1345–1356.
- 5 Menshaw, A. – Eltonob, A. A. – Barkat, S. A., et al.: Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and metaanalysis of randomized controlled trials. *Melanoma Res*, 27. 6. 2018, doi: 10.1097/CMR.0000000000000467, Epub před tiskem.
- 6 Long, G. V. – Atkinson, V. – Cebon, J. S., et al.: Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. *Lancet Oncol*, 2017, 18, s. 1202–1210.
- 7 Retseck, J. – Van der Weele, R. – Lin, H. M., et al.: Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. *J Immunother*, 2016, 4, s. 38.
- 8 Chae, Y. K. – Arya, A. – Iams, W. J., et al.: Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). *J Immunother*, 2018, 6, s. 39, doi: 10.1186/s40425-018-0349-3.
- 9 Schadendorf, D. – Wolchok, J. D. – Hodi, F. S., et al.: Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. *J Clin Oncol*, 2017, 35, s. 3807–3814.
- 10 Long, G. V. – Atkinson, V. – Lo, S., et al.: Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncology*, 2018, 19, s. 672–681.
- 11 Hellmann, M. D. – Callahan, M. K. – Awad, M. M., et al.: Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. *Cancer Cell*, 2018, 33, s. 853–861.

## Léčba generalizovaného maligního melanomu kombinací BRAF inhibitoru dabrafenibu s MEK inhibitorem trametinibem – kazuistika

MUDr. Michaela Fridrichová Ústav radiační onkologie Nemocnice Na Bulovce, Praha

- 1 Long, G. V. – Stroyakovskiy, D. – Gogas, H., et al.: Combined BRAF and MEK inhibition versus BRAF inhibitory one in melanoma. *N Engl J Med*, 2014, 371, s. 1877–1888, doi: 10.1056/NEJMoa1406037.
- 2 Long, G. V. – Flaherty, K. T. – Stroyakovskiy, D., et al.: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Ann Oncol*, 2017, 28, s. 1631–1639, doi: 10.1093/annonc/mdx176.
- 3 Ugurel, S. – Röhm, J. – Ascierto, P. A., et al.: Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. *Eur J Cancer*, 2017, 83, s. 247–257, doi: 10.1016/j.ejca.2017.06.028.

## Pacient s mnohočetným recidivujícím bazocelulárním karcinomem – kazuistika

MUDr. Renata Emmerová Komplexní onkologické centrum, KN Liberec, a. s., Liberec

- 1 Roš, T. – Gajić, R. – Rajić, N., et al.: Basal cell carcinoma: a frequent challenge. *Serb J Dermatol Venerol*, 2012, 4, s. 5–17.
- 2 Alter, M. – Hillen, U. – Leiter, U., et al.: Current diagnosis and treatment of basal cell carcinoma. *CME-Article JDDG*, 2015, s. 863–875.
- 3 Basset-Sequin, N. – Hauschild, A. – Kuntzfeld, R., et al.: Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open label trial. *Eur J Cancer*, 2017, 86, s. 334–348.
- 4 Alfieri, S. – Bergamini, C. – Granata, R., et al.: Retreatment with vismodegib after progression in advanced basal cell carcinoma: first-time report of a single-institution experience. *Target Oncol*, 2018, 13, s. 253–256.
- 5 Sekulic, A. – Migden, M. R. – Oro, A. E., et al.: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. *New Eng J Med*, 2012, s. 2171–2179.
- 6 Xie, J. – Bartels, M. C. – Barton, W. S.: Hedgehog signaling in human cancer. *Onco Targets Ther*, 2013, 6, s. 1425–1435.

## Lenvatinib – nově dostupná možnost léčby radiojod refrakterního diferencovaného karcinomu štítné žlázy

MUDr. Hana Švébišová, Ph.D. Onkologická klinika a LF UP, Olomouc

- 1 Vlček, P.: Diferencovaný karcinom štítné žlázy – nový pohled na jeho léčbu. *Onkologie*, 2011, 5.
- 2 Němec, J. – Bílek, R. – Zamrazil, V. – Dvořák, J. – Racek, P. – Vlček, P.: The prognostic value of plasma Thyroglobulin at the time of hypothyroidism in the differentiated thyroid cancer. *Nukl Med*, 1995, 34, A179.
- 3 Tuttle, R. M., et al.: Novel concepts for initiating multitargeted kinase inhibitors in radioiodine refractory differentiated thyroid cancer. *Best Pract Res Clin Endocrinol Metab*, 2017, 31, s. 295–305.
- 4 Brose, S. M., et al.: Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. *J Clin Oncol*, 2017, 1–8.
- 5 Schlumberger, M., et al.: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. *New Eng J Med*, 2015, 372, s. 621–630.
- 6 NCCN guidelines: Thyroid Cancer, Ver. 1.2018. Dostupné z: [https://www.nccn.org/professionals/physician\\_gls/pdf/thyroid.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf), vyhledáno 20. 9. 2018.

## Kam směřuje léčba chronické myeloidní leukemie inhibitory tyrosinové kinázy?

MUDr. Hana Klamová, Ph.D. Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie 1. LF UK, Praha

- 1 Drucker, B. J. – Guilhot, F. – O'Brien, S. G., et al.: Five-year follow-up patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med*, 2000, s. 2408–2417.
- 2 Hehlmann, R. – Hochhaus, A. – Baccarani, M., et al.: On behalf of the European Leukemia Net: Chronic myeloid leukemia. *Lancet*, 2007, 370, s. 342–350.
- 3 Huang, X. – Cortes, J. – Kantarjian, H.: Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor. *Cancer*, 2012, 118, s. 3121–3127.
- 4 Baccarani, M. – Deininger, M. W. – Rosti, G., et al.: European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. *Blood*, 2013, 122, s. 872–884.
- 5 Mayer, J., ed., et al.: *Léčebné postupy v hematologii: doporučení České hematologické společnosti ČLS JEP*. Praha, Česká hematologická společnost České lékařské společnosti J. E. Purkyně, 2016.
- 6 Rousselot, P. – Huguier, F. – Rea, D., et al.: Imatinib mesylate discontinuation on patients with chronic myeloid leukemia in complete molecular remission for more than 2 years. *Blood*, 2007, 109, s. 68–70.
- 7 Mahon, F. X. – Read, D. – Guilhot, J., et al.: Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective Stop Imatinib (STIM) trial. *Lancet Oncol*, 2010, 11, s. 1029–1035.
- 8 Etienne, G. – Read, D. – Guilhot, J., et al.: Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. *J Clin Oncol*, 2017, 35, s. 298.
- 9 Read, D. – Nicolini, F. E. – Tulliez, M., et al.: Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the

- STOP 2G-TKI study. *Blood*, 2017, 129, s. 846–854.
- 10 Saussele, S. – Richter, J. – Hochhaus, A., et al.: The concept of treatment-free remission in chronic myeloid leukemia. *Leukemia*, 2016, 30, s. 1638–1647.
  - 11 Saussele, S. – Richter, J. – Guilhot, J., et al.: First interim analysis of a Pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial. *Haematologica*, 2014, 99, s. 792.
  - 12 Mahon, X. F., et al.: Interim analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in CML: The EURO-SKI study. *Blood*, 2014, 124, abstrakt 151.
  - 13 Jabbour, E. – Kantarjian, H.: Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. *Am J Hematol*, 2018, 93, s. 442–459.
  - 14 Saussele, S. – Richter, J. – Guilhot, J., et al.: Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised trial. *Lancet Oncol*, 2018, 19, s. 747–757.
  - 15 Clark, C. E. – Polydoros, F. – Apperley, J. F., et al.: De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. *Lancet Haematol*, 2017, s. 310–316.
  - 16 Russo, D. – Martinelli, G. – Malagola, M., et al.: Effect and outcome of policy intermittent treatment imatinib in elderly patients with chronic myeloid leukemia. *Blood*, 2013, 121, s. 5138–5144.
  - 17 Ambruzese, E. – Trawinska, M. M. – Fabritti, S. M., et al.: Management of pregnant chronic myeloid leukemia patients. *Expert Rev Hematol*, 2016, 9, s. 781–791.
  - 18 Holyoake, L. – Vetrie, D.: The chronic myeloid leukemia stem cell: stemming the tide or persistence. *Blood*, 2017, 129, s. 1595–1606.
  - 19 Hjorth-Hansen, H. – Stentoft, J. – Richter, J., et al.: Safety and efficacy of the combination of pegylated-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. *Leukemia*, 2016, 30, s. 1853–1860.

## Hodgkinův lymfom u starších nemocných

MUDr. Alice Sýkorová, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové

MUDr. Heidi Móciková, Ph.D. Oddělení klinické hematologie, FN Královské Vinohrady a 3. LF UK, Praha

- 1 Hlavní stránka | ÚZIS ČR. Dostupné z: <http://www.uzis.cz/links/web-blink>, vyhledáno 29. 6. 2018.
- 2 Stark, G. L., et al.: Hodgkin's disease in the elderly: a population-based study. *Br J Haematol*, 2002, 119, s. 432–440.
- 3 Erdkamp, F. L. – Breed, W. P. – Bosch, L. J., et al.: Hodgkin disease in the elderly: A registry-based analysis. *Cancer*, 1992, 70, s. 830–834.
- 4 Levis, A., et al.: Probability of cure in elderly Hodgkin's disease patients. *Haematologica*, 1994, 79, s. 46–54.
- 5 Mir, R., et al.: Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. *Cancer*, 1993, 71, s. 1857–1866.
- 6 Roy, P. – Vaughan Hudson, G. – Vaughan Hudson, B., et al.: Long-term survival in Hodgkin's disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries. *Eur J Cancer*, 2000, 36, s. 384–389.
- 7 Pulte, D., et al.: Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. *Br J Haematol*, 2014, 164, s. 851–857.
- 8 Evens, A. M., et al.: A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. *Blood*, 2012, 119, s. 692–695.
- 9 Stamatoullas, A., et al.: Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. *Br J Haematol*, 2015, 170, s. 179–184.
- 10 Enblad, G. – Gustavsson, A. – Sundström, C., et al.; Swedish Lymphoma Study Group: Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy. *Acta Oncol*, 2002, 41, s. 659–667.
- 11 van Spronsen, D. J. – Janssen-Heijnen, M. L. – Breed, W. P., et al.: Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993–1996. *Ann Hematol*, 1999, 78, s. 315–319.
- 12 Thys, A. – Saada, E. – Gastaud, L., et al.: Hodgkin's lymphoma in older patients: an orphan disease? *Mediterr J Hematol Infect Dis*, 2014, 6, e2014050.
- 13 Guinee, V. F., et al.: The prognosis of Hodgkin's disease in older adults. *J Clin Oncol*, 1991, 9, s. 947–953.
- 14 Kim, H. K. – Silver, B. – Li, S., et al.: Hodgkin's disease in elderly patients (> or =60): clinical outcome and treatment strategies. *Int J Radiat Oncol Biol Phys*, 2003, 56, s. 556–560.
- 15 Specht, L. – Nissen, N. I.: Hodgkin's disease and age. *Eur J Haematol*, 1989, 43, s. 127–135.
- 16 Engert, A., et al.: Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. *J Clin Oncol*, 2005, 23, s. 5052–5060.
- 17 Landgren, O., et al.: Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. *Haematologica*, 2003, 88, s. 438–444.
- 18 Ballova, V., et al.: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). *Ann Oncol*, 2005, 16, s. 124–131.
- 19 Hasenclever, D. – Diehl, V.: A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. *N Engl J Med*, 1998, 339, s. 1506–1514.
- 20 Cuccaro, A., et al.: Prognostic factors in Hodgkin lymphoma. *Mediterr J Hematol Infect Dis*, 2014, 6.
- 21 Jagadeesh, D. – Diefenbach, C. – Evens, A. M.: XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. *Hematol Oncol*, 2013, 31, suppl. 1, s. 69–75.
- 22 Enblad, G. – Glimelius, B. – Sundström, C.: Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. *Ann Oncol*, 1991, 2, s. 297–302.
- 23 Wedelin, C., et al.: Prognostic factors in Hodgkin's disease with special reference to age. *Cancer*, 1984, 53, s. 1202–1208.
- 24 Walker, A., et al.: Survival of the older patient compared with the younger patient with Hodgkin's disease. Influence of histologic type, staging, and treatment. *Cancer*, 1990, 65, s. 1635–1640.
- 25 Levis, A., et al.: VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. *Ann Oncol*, 2004, 15, s. 123–128.
- 26 Armstrong, A. A., et al.: Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis. *Leukemia*, 1998, 12, s. 1272–1276.
- 27 Klimm, B. – Diehl, V. – Engert, A.: Hodgkin's lymphoma in the elderly: a different disease in patients over 60. *Oncology* (Williston Park, N.Y.), 2007, 21, s. 982–990; discussion 990, 996, 998 passim.
- 28 Greaves, P., et al.: Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. *J Clin Oncol*, 2013, 31, s. 256–262.
- 29 Kelley, T. W. – Pohlman, B. – Elson, P., et al.: The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. *Am J Clin Pathol*, 2007, 128, s. 958–965.
- 30 Sieber, M. – Engert, A. – Diehl, V.: Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group. *Ann Oncol*, 2000, 11, suppl. 1, s. 81–85.
- 31 Wildiers, H., et al.: International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. *J Clin Oncol*, 2014, 32, s. 2595–2603.
- 32 Hurria, A., et al.: Implementing a geriatric assessment in cooperative clinical cancer trials: CALGB 360401. *J Clin Oncol*, 2011, 29, s. 1290–1296.
- 33 Puts, M. T. E., et al.: An update on a systematic review of the use of geriatric assessment for older adults in oncology. *Ann Oncol*, 2014, 25, s. 307–315.
- 34 Böll, B., et al.: ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. *J Clin Oncol*, 2013, 31, s. 1522–1529.
- 35 Böll, B., et al.: Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. *J Clin Oncol*, 2013, 31, s. 4431–4437.
- 36 Evens, A. M., et al.: The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. *Br J Haematol*, 2013, 161, s. 76–86.
- 37 Böll, B., et al.: Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. *Blood*, 2016, 127, s. 2189–2192.
- 38 Zallof, F., et al.: Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). *Br J Haematol*, 2016, 172, s. 879–888.
- 39 Proctor, S. J., et al.: Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. *Blood*, 2012, 119, s. 6005–6015.
- 40 Halbguth, T. V., et al.: Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). *Blood*, 2010, 116, s. 2026–2032.
- 41 Engert, A., et al.: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. *N Engl J Med*, 2010, 363, s. 640–652.
- 42 Behringer, K., et al.: Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. *Lancet*, 2015, 385, s. 1418–1427.
- 43 Radford, J., et al.: Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. *N Engl J Med*, 2015, 372, s. 1598–1607.
- 44 Raemaekers, J. M. M., et al.: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. *J Clin Oncol*, 2014, 32, s. 1188–1194.
- 45 Specht, L., et al.: Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILOG). *Int J Radiat Oncol Biol Phys*, 2014, 89, s. 854–862.
- 46 Longo, D. L., et al.: Twenty years of MOPP therapy for Hodgkin's disease. *J Clin Oncol*, 1986, 4, s. 1295–1306.
- 47 Bonadonna, G. – Valagussa, P. – Santoro, A.: Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. *Ann Intern Med*, 1986, 104, s. 739–746.
- 48 Duggan, D. B., et al.: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. *J Clin Oncol*, 2003, 21, s. 607–614.
- 49 Bartlett, N. L. – Rosenberg, S. A. – Hoppe, R. T., et al.: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. *J Clin Oncol*, 1995, 13, s. 1080–1088.
- 50 Hoskin, P. J., et al.: Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. *J Clin Oncol*, 2009, 27, s. 5390–5396.
- 51 Weekes, C. D., et al.: Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. *J Clin Oncol*, 2002, 20, s. 1087–1093.
- 52 Macpherson, N., et al.: Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study. *Leuk Lymphoma*, 2002, 43, s. 1395–1402.
- 53 Kolstad, A., et al.: Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. *Leuk Lymphoma*, 2007, 48, s. 570–576.
- 54 Johnson, P., et al.: Adapted treatment guided by interim PET-CT Scan in advanced Hodgkin's lymphoma. *N Engl J Med*, 2016, 374, s. 2419–2429.
- 55 Younes, A., et al.: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol*, 2012, 30, s. 2183–2189.
- 56 Younes, A., et al.: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. *N Engl J Med*, 2010, 363, s. 1812–1821.
- 57 Chen, R., et al.: Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. *J Clin Oncol*, 2017, 35, s. 2125–2132.
- 58 Ansell, S. M.: Nivolumab in the treatment of Hodgkin lymphoma. *Clin Cancer Res*, 2017, 23, s. 1623–1626.
- 59 Gopal, A. K., et al.: Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. *Leuk Lymphoma*, 2014, 55, 2328–2334.
- 60 Forero-Torres, A., et al.: Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. *Blood*, 2015, 126, s. 2798–2804.
- 61 Friedberg, J. W., et al.: Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. *Blood*, 2017, doi:10.1182/blood-2017-06-787200.
- 62 Connors, J. M., et al.: Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. *N Engl J Med*, 2018, 378, s. 331–344.
- 63 Evens, A. M., et al.: Sequential brentuximab vedotin (Bv) before and after adriamycin, vinblastine, and dacarbazine (Bv-ABVD) for older patients with untreated classical Hodgkin lymphoma (CHL): Final results from a multicenter phase II study. *Blood*, 2017, 130, s. 733.
- 64 Younes, A., et al.: Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncol*, 2016, 17, s. 1283–1294.
- 65 Armand, P., et al.: Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. *J Clin Oncol*, 2018, 36, s. 1428–1439.
- 66 Armand, P., et al.: Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab

vedotin failure. *J Clin Oncol*, 2016, 34, s. 3733–3739.  
67 **Herrera, A. F., et al.**: Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. *Blood*, 2018, 131, s. 1183–1194.

68 **Böll, B., et al.**: Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. *Blood*, 2011, 118, s. 6292–6298.  
69 **Ramchandren, R., et al.**: Nivolumab for newly diagnosed

advanced-stage classical Hodgkin lymphoma (cHL): Results from the phase 2 Checkmate 205 study. *Blood*, 2017, 130, s. 651.

## Můžeme upravit intenzitu úvodní léčby u Hodgkinova lymfomu podle výsledku průběžného PET?

doc. MUDr. Vít Procházka, Ph.D. | MUDr. Marie Lukášová Hemato-onkologická klinika Fakultní nemocnice Olomouc

MUDr. Lenka Henzlová, Ph.D. Klinika nukleární medicíny Fakultní nemocnice Olomouc

prof. MUDr. Tomáš Papajík, CSc. Hemato-onkologická klinika Fakultní nemocnice Olomouc

- 1 **Kanzler, H. – Kuppers, R. – Hansmann, M. L., et al.**: Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. *J Exp Med*, 1996, 184, s. 1495–1505.
- 2 **Swerdlow, S. H. – Campo, E. – Harris, N. L., et al.**: *WHO classification of tumours of haematopoietic and lymphoid tissues*. IARC, Lyon 2008.
- 3 **Novotary 2011 ČR**. Praha, Ústav zdravotnických informací a statistiky ČR, 2015, s. 90–94.
- 4 **Canellos, G. P. – Rosenberg, S. A. – Friedberg, J. W., et al.**: Treatment of Hodgkin lymphoma: a 50-year perspective. *J Clin Oncol*, 2014, 32, s. 163–168.
- 5 **Cheson, B. D.**: The International Harmonization Project for response criteria in lymphoma clinical trials. *Hematol Oncol Clin North Am*, 2007, 21, s. 841–854.
- 6 **Kooperativní lymfomová skupina**: *Diagnostické a léčebné postupy u nemocných s maligními lymfomy – IX. vydání*. HK CREDIT, Hradec Králové 2016.
- 7 **Kanoun, S. – Rossi, C. – Berriolo-Riedinger, A., et al.**: Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. *Eur J Nucl Med Mol Imaging*, 2014, 41, s. 1735–1743.
- 8 **Cottreau, A. S. – Versari, A. – Loft, A., et al.**: Prognostic value of baseline metabolic tumour volume in early stage Hodgkin's lymphoma in the standard arm of H10 trial. *Blood*, 2018, 131, s. 1456–1463.
- 9 **Akhtari, M. – Milgrom, S. A. – Pinnix, C. C., et al.**: Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. *Blood*, 2018, 131, s. 84–94.
- 10 **Juweid, M. E. – Stroobants, S. – Hoekstra, O. S., et al.**: Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. *J Clin Oncol*, 2007, 25, s. 571–578.
- 11 **Meignan, M. – Gallamini, A. – Meignan, M., et al.**: Report on the First International Workshop on Interim-PET-Scan in Lymphoma. *Leuk Lymphoma*, 2009, 50, s. 1257–1260.
- 12 **Cheson, B. D. – Fisher, R. I. – Barrington, S. F., et al.**: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol*, 2014, 32, s. 3059–3068.
- 13 **Gallamini, A. – Hutchings, M. – Rigacci, L., et al.**: Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostics core in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. *J Clin Oncol*, 2007, 25, s. 3746–3752.
- 14 **Zinzani, P. L. – Rigacci, L. – Stefoni, V., et al.**: Early interim 18F-FDG PET in Hodgkin's lymphoma: Evaluation on 304 patients. *Eur J Nucl Med Mol Imaging*, 2012, 39, s. 4–12.
- 15 **Hutchings, M. – Loft, A. – Hansen, M., et al.**: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. *Blood*, 2006, 107, s. 52–59.
- 16 **Gallamini, A. – Barrington, S. F. – Biggi, A., et al.**: The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed during the interpretation criteria of the Deauville five-point scale. *Haematologica*, 2014, 99, s. 1107–1113.
- 17 **Radford, J. – Illidge, T. – Counsell, N., et al.**: Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. *N Engl J Med*, 2015, 372, s. 1598–1607.
- 18 **Raemaekers, J. M. M. – André, M. P. E. – Federico, M., et al.**: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. *J Clin Oncol*, 2014, 32, s. 1188–1194.
- 19 **André, M. P. E. – Girinsky, T. – Federico, M., et al.**: Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 trial. *J Clin Oncol*, 2017, 35, s. 1786–1794.
- 20 **Gallamini, A. – Patti, C. – Viviani, S., et al.**: Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with an interim-PET positive after two ABVD courses. *Br J Haematol*, 2011, 152, s. 551–560.
- 21 **Press, O. W. – Li, H. – Schöder, H., et al.**: US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. *J Clin Oncol*, 2016, 34, s. 2020–2027.
- 22 **Johnson, P. – Federico, M. – Kirkwood, A., et al.**: Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. *N Engl J Med*, 2016, 374, s. 2419–2429.
- 23 **Casasnovas, O. – Brice, P. – Bouabdallah, R., et al.**: Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Interim analysis of the AHL2011 Lysa study. *Blood*, 2015, 126, s. 577.
- 24 **Borchmann, P. – Haverkamp, H. – Lohri, A., et al.**: Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): An open-label, international, randomised phase 3 study by the German Hodgkin Study Group. *Lancet Oncol*, 2017, 18, s. 454–463.
- 25 **Ulaner, G. A. – Lilienstein, J. – Gönen, M., et al.**: False-positive [18F] fluorodeoxyglucose-avid lymph nodes on positron emission tomography – computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma. *J Clin Oncol*, 2014, 32, s. 51–56.
- 26 **Kaalep, A. – Sera, T. – Oyen, W., et al.**: EANM/EARL FDG-PET/CT accreditation – summary results from the first 200 accredited imaging systems. *Eur J Nucl Med Mol Imaging*, 2018, 45, s. 412–422.
- 27 **Cuccaro, A. – Annunziata, S. – Cupelli, E., et al.**: CD68+ cell count, early evaluation with PET and plasma TARCs levels predict response in Hodgkin lymphoma. *Cancer Med*, 2016, 5, s. 398–406.

## Primární lymfom centrální nervové soustavy – kam kráčíš?

MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FNKV a 3. LF UK, Praha

- 1 **Baraniskin, A. – Chomiak, M. – Ahle, G., et al.**: MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS. *J Neurooncol*, 2018, 137, s. 463–468.
- 2 **Abrey, L. E. – Ben-Porat, L. – Panageas, K. S., et al.**: Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. *J Clin Oncol*, 2006, 24, s. 5711–5715.
- 3 **Ferreri, A. J. – Blay, J. Y. – Reni, M., et al.**: Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. *J Clin Oncol*, 2003, 21, s. 266–272.
- 4 **Rubenstein, J. L. – Hsi, E. D. – Johnson, J. L., et al.**: Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). *J Clin Oncol*, 2013, 31, s. 3061–3068.
- 5 **Kreher, S. – Jöhrens, K. – Strehlow, F., et al.**: Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. *Neuro Oncol*, 2015, 17, s. 1016–1021.
- 6 **Bonzheim, I. – Giese, S. – Deuter, C., et al.**: High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. *Blood*, 2015, 126, s. 76–79.
- 7 **Ferreri, A. J. – Cwynarski, K. – Pulczynski, E., et al.**: Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATHrix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. *Lancet Haematol*, 2016, 3, s. 217–227.
- 8 **Mocikova, H. – Pytlik, R. – Sykorova, A., et al.**: Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. *Leuk Lymphoma*, 2016, 57, s. 2777–2783.
- 9 **Fritsch, K. – Kasenda, B. – Schorb, E., et al.**: High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). *Leukemia*, 2017, 31, s. 846–852.
- 10 **Ferreri, A. J. M. – Cwynarski, K. – Pulczynski, E., et al.**: Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. *Lancet Haematol*, 2017, 4, s. e510–e523.
- 11 **Nayak, L. – Iwamoto, F. M. – LaCasce, A., et al.**: PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. *Blood*, 2017, 129, s. 3071–3073.
- 12 **Grommes, C. – Pastore, A. – Palaskas, N., et al.**: Ibrutinib unmasks critical role of Bruton Tyrosine Kinase in primary CNS lymphoma. *Cancer Discov*, 2017, 7, s. 1018–1029.
- 13 **Lionakis, M. S. – Dunleavy, K. – Roschewski, M., et al.**: Inhibition of B cell receptor signaling by Ibrutinib in primary CNS lymphoma. *Cancer Cell*, 2017, 31, s. 833–843.e5.
- 14 **Tun, H. W. – Johnston, P. B. – Grommes, C., et al.**: Phase I clinical trial on pomalidomide and dexamethasone in treating patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) or primary vitreoretinal lymphoma (PVRL). *J Clin Orthod*, 2017, 35, suppl. 15, s. 7516–7516.
- 15 **Rubenstein, J. L. – Fraser, E. – Formaker, P., et al.**: Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma. *J Clin Oncol*, 2016, 34, s. 7502.
- 16 **Korfel, A. – Schlegel, U. – Herrlinger, U., et al.**: Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma. *J Clin Oncol*, 2016, 34, s. 1757–1763.

## Úspěšná léčba obinutuzumabem s chlorambucilem u staršího pacienta s masivní lymfadenopatií – kazuistika

MUDr. Martin Špaček, Ph.D. I. interní klinika – klinika hematologie 1. LF UK a VFN, Praha

- 1 **Goede, V., et al.**: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med*, 2014, 370, s. 1101–1110.
- 2 **Goede, V., et al.**: Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. *EHA*, 2018, abstrakt S151.



# Úspěšná léčba venetoklaxem u pacientky s abruptivním relapsem předléčené relabující/refrakterní chronické lymfocytární leukemie po selhání terapie idelalisibem a ibrutinibem – kazuistika

MUDr. Peter Turcsányi, Ph.D. | MUDr. Renata Urbanová, Ph.D. | prof. MUDr. Tomáš Papajík CSc.

Hemato-onkologická klinika FN Olomouc

- 1 Seymour, J. F. – Kipps, T. J. – Eichhorst, B., et al.: Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. *N Engl J Med*, 2018, 378, s. 1107–1120.
- 2 Jones, J. A. – Mato, A. R. – Wierda, W. G., et al.: Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2018, 19, s. 65–75.

## Aktuální léčba relabované a refrakterní chronické lymfocytární leukemie – kazuistika

MUDr. Martin Šimkovič, Ph.D. IV. interní hematologická klinika, FN Hradec Králové

- 1 Goede, V. – Fischer, K. – Busch, R., et al.: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med*, 2014, 370, s. 1101–1110, doi:10.1056/NEJMoa1313984.
- 2 Goede, V. – Fischer, K. – Engelke, A., et al.: Obinutuzumab as front-line treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. *Leukemia*, 2015, 29, s. 1602–1604, doi: 10.1038/leu.2015.14.
- 3 O'Brien, S. – Jones, J. A. – Coutre, S. E., et al.: Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. *Lancet Oncol*, 2016, 17, s. 1409–1418, DOI: [https://doi.org/10.1016/S1470-2045\(16\)30212-1](https://doi.org/10.1016/S1470-2045(16)30212-1).
- 4 Brown, J. R. – Hillmen, P. – O'Brien, S., et al.: Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. *Leukemia*, 2018, 32, s. 83–91, doi:10.1038/leu.2017.175.
- 5 Furman, R. R. – Sharman, J. P. – Coutre, S. E., et al.: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med*, 2014, 370, s. 997–1007, doi:10.1056/NEJMoa1315226.
- 6 Stilgenbauer, S. – Eichhorst, B. – Schetelig, J., et al.: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. *Lancet Oncol*, 2016, 17, s. 768–778.
- 7 Jones, J. A. – Mato, A. R. – Wierda, W. G., et al.: Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2018, 19, s. 65–75.

## Management lymfomů v těhotenství

MUDr. Jan Kořen I. interní klinika – klinika hematologie, 1. LF UK a VFN, Praha

- 1 Muller, A. M. – Ihorst, G. – Mertelsmann, R., et al.: Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. *Ann Hematol*, 2005, 84, s. 1–12.
- 2 Diamond, C. – Taylor, T. H. – Aboumrak, T., et al.: Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. *Cancer*, 2006, 106, s. 128–135.
- 3 Bachanova, V. – Connors, J. M.: Hodgkin lymphoma in pregnancy. *Curr Hematol*, 2013, 8, s. 211–217.
- 4 Yamasaki, M. – Mukai, A. – Ohba, M., et al.: Genistein induced apoptotic cell death in adult T-cell leukemia cells through estrogen receptors. *Biosci Biotechnol Biochem*, 2010, 74, s. 2113–2115.
- 5 Cohen-Kerem, R. – Railton, C. – Oren, D., et al.: Pregnancy outcome following non-obstetric surgical intervention. *Am J Surg*, 2005, 190, s. 467–473.
- 6 Zanotti-Fregonara, P. – Jan, S. – Taieb, D., et al.: Absorbed 18F-FDG dose to the fetus during early pregnancy. *J Nucl Med*, 2010, 51, s. 803–805.
- 7 Shellock, F. G. – Kanal, E.: Policies, guidelines, and recommendations for MR imaging safety and patient management. SMRI Safety Committee. *J Magn Reson Imaging*, 1991, 1, s. 97–101.
- 8 Muhler, M. R. – Clement, O. – Salomon, L. J., et al.: Maternofetal pharmacokinetics of a gadolinium chelate contrast agent in mice. *Radiology*, 2011, 258, s. 455–460.
- 9 Abadi, U. – Koren, G. – Lishner, M.: Leukemia and lymphoma in pregnancy. *Hematol Oncol Clin North Am*, 2011, 25, s. 277–291.
- 10 Doll, D. C. – Ringenberg, Q. S. – Yarbrow, J. W.: Management of cancer during pregnancy. *Arch Intern Med*, 1988, 148, s. 2058–2064.
- 11 Chakravarty, E. F. – Murray, E. R. – Kelman, A., et al.: Pregnancy outcomes after maternal exposure to rituximab. *Blood*, 2011, 117, s. 1499–1506.
- 12 Streffer, C. – Shore, R. – Konermann, G., et al.: Biological effects after prenatal irradiation (embryo and fetus). A report of the International Commission on Radiological Protection. *Ann ICRP*, 2003, 33, s. 5–206.
- 13 Lishner, M., et al.: Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. *J Clin Oncol*, 2015, 34, s. 501–508.
- 14 Dale, D. C. – Cottle, T. E. – Fier, C. J., et al.: Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. *Am J Hematol*, 2003, 72, s. 82–93.
- 15 Lishner, M. – Zemlickis, D. – Degendorfer, P., et al.: Maternal and foetal outcome following Hodgkin's disease in pregnancy. *Br J Cancer*, 1992, 65, s. 114–117.
- 16 Evens, A. M. – Advani, R. – Press, O. W., et al.: Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. *J Clin Oncol*, 2013, 31, s. 4132–4139.
- 17 Koren, G. – Lishner, M. – Santiago, S.: *The Motherisk Guide to Cancer in Pregnancy and Lactation*. Toronto, Kanada, Motherisk program, 2005.
- 18 Cardonick, E. – Iacobucci, A.: Use of chemotherapy during human pregnancy. *Lancet Oncol*, 2004, 5, s. 283–291.
- 19 Amant, F. – Van Calsteren, K. – Halaska, M. J., et al.: Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: An observational study. *Lancet Oncol*, 2012, 13, s. 256–264.
- 20 Aviles, A. – Neri, N.: Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. *Clin Lymphoma*, 2001, 2, s. 173–177.
- 21 Lishner, M. – Zemlickis, D. – Sutcliffe, S. B., et al.: Non-Hodgkin's lymphoma and pregnancy. *Leuk Lymphoma*, 1994, 14, s. 411–413.
- 22 Pinnix, C. C. – Osborne, E. M. – Chihara, D., et al.: Maternal and fetal outcomes after therapy for Hodgkin or non-Hodgkin lymphoma diagnosed during pregnancy. *JAMA Oncol*, 2016, 2, s. 1065–1069.

## Příznivý vliv dasatinibu na kompenzaci diabetu u pacienta s chronickou myeloidní leukemií – kazuistika

MUDr. Petra Bělohávková, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové

- 1 Baccharani, M. – Deininger, M. – Rosti, G., et al.: European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. *Blood*, 2013, 122, s. 872–884.
- 2 Steegmann, J. L. – Baccharani, M. – Breccia, M., et al.: European Leukemia Net recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. *Leukemia*, 2016, 30, s. 57–64.
- 3 Caldemeyer, L. – Dugan, M. – Edwards, J., et al.: Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. *Curr Hematol Malig Rep*, 2016, 11, s. 71–79.
- 4 Breccia, M. – Muscaritoli, M. – Aversa, Z., et al.: Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. *J Clin Oncol*, 2004, 22, s. 4653–4655.
- 5 Ono, K. – Suzushima, H. – Watanabe, Y., et al.: Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patients with type 2 diabetes mellitus. *Intern Med*, 2012, 51, s. 2763–2766.
- 6 Agostino, N. M. – Chinchilli, V. M. – Lynch, C. J., et al.: Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. *J Oncol Pharm Pract*, 2011, 17, s. 197–202.
- 7 Iizuka, K. – Niwa, H. – Kato, T., et al.: Dasatinib improves insulin sensitivity and affects lipid metabolism in a patient with chronic myeloid leukemia. *BMJ Case Rep*, 2016, pii: bcr2015214284, doi: 10.1136/bcr-2015-214284.
- 8 Romero-Ventosa, E. Y. – Otero-Millán, L. – González-Costas, S., et al.: Effect of tyrosinekinase inhibitors on the glucose levels in diabetic and nondiabetic patients. *Indian J Cancer*, 2017, 54, s. 136–143.
- 9 Fountas, A. – Diamantopoulos, L. N. – Tsatsoulis, A.: Tyrosine kinase inhibitors and diabetes: A novel treatment paradigm? *Trends Endocrinol Metab*, 2015, 26, s. 643–656.
- 10 Fountas, A. – Tigas, S. – Giotaki, Z., et al.: Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment. *Hormones*, 2015, 14, s. 438–441.

# Nová doporučení pro léčbu chronické lymfocytární leukemie a ibrutinib

MUDr. Jakub Trizuljak | prof. MUDr. Michael Doubek, Ph.D. Interní hematologická a onkologická klinika, LF a FN Brno, Středoevropský technologický institut (CEITEC) Masarykovy univerzity, Brno

- 1 Hallek, M.: Chronic Lymphocytic Leukemia: 2017 update on diagnosis, risk stratification, and treatment. *Am J Hematol*, 2017, 92, s. 946–965.
- 2 Cramer, P. – Hallek, M. – Eichhorst, B.: State-of-the-art treatment and novel agents in chronic lymphocytic leukemia. *Oncol Res Treat*, 2016, 39, s. 25–32.
- 3 Byrd, J. C. – Furman, R. R. – Coutre, S. E., et al.: Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. *Blood*, 2015, 125, s. 2497–2506.
- 4 Jemal, A. – Siegel, R. – Ward, E., et al.: Cancer statistics, 2007. *CA Cancer J Clin*, 2007, 57, s. 43–66.
- 5 Panovská, A. – Doubek, M. – Brychtová, Y. – Mayer, J.: Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). *Clin Lymphoma Myeloma Leuk*, 2010, 10, s. 297–300.
- 6 Kikushige, Y. – Ishikawa, F. – Miyamoto, T., et al.: Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. *Cancer Cell*, 2011, 20, s. 246–259.
- 7 Landau, D. A. – Tausch, E. – Taylor-Weiner, A. N., et al.: Mutations driving CLL and the revolution in progression and relapse. *Nature*, 2015, 526, s. 525–530.
- 8 Zenz, T. – Mertens, D. – Kupper, R., et al.: From pathogenesis to treatment of chronic lymphocytic leukaemia. *Nat Rev Cancer*, 2010, 10, s. 37–50.
- 9 Dohner, H. – Stilgenbauer, S. – James, M. R., et al.: 11q deletions identify new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. *Blood*, 1997, 89, s. 2516–2522.
- 10 Seiffert, M. – Dietrich, S. – Jethwa, A., et al.: Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. *Leuk Lymphoma*, 2012, 53, s. 1023–1031.
- 11 Hallek, M. – Fischer, K. – Fingerle-Rowson, G., et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *Lancet*, 2010, 376, s. 1164–1174.
- 12 Zenz, T. – Vollmer, D. – Trbusek, M., et al.: TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. *Leukemia*, 2010, 24, s. 2072–2079.
- 13 Hallek, M. – Cheson, B. D. – Catovsky, D., et al.: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*, 2018, 131, s. 2745–2760.
- 14 Dearden, C.: B- and T-cell prolymphocytic leukemia: antibody approaches. *Hematology Am Soc Hematol Educ Program*, 2012, s. 645–651.
- 15 Strati, P. – Shanafelt, T. D.: Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. *Blood*, 2015, 126, s. 454–462.
- 16 Rai, K. R. – Sawitsky, A. – Cronkite, E. P., et al.: Clinical staging of chronic lymphocytic leukemia. *Blood*, 1975, 46, s. 219–234.
- 17 Binet, J. L. – Auquier, A. – Dighiero, G., et al.: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. *Cancer*, 1981, 48, s. 198–204.
- 18 Dohner, H. – Stilgenbauer, S. – Benner, A., et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med*, 2000, 343, s. 1910–1916.
- 19 Ghia, P. – Stamatopoulos, K. – Belessi, C., et al.: ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. *Leukemia*, 2007, 21, s. 1–3.
- 20 Malcikova, J. – Pavlova, S. – Kozubik, K. S., et al.: TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia. *Hum Mutat*, 2014, 35, s. 663–671.
- 21 Malcikova, J. – Tausch, E. – Rossi, D., et al.: ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia – update on methodological approaches and results interpretation. *Leukemia*, 2018, 32, s. 1070–1080.
- 22 Eichhorst, B. – Robak, T. – Montserrat, E., et al.: Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2015, 26, suppl. 5, s. v78–v84.
- 23 Dreger, P. – Schetelig, J. – Andersen, N., et al.: Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? *Blood*, 2014, 124, s. 3841–3849.
- 24 Hallek, M.: Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. *Am J Hematol*, 2013, 88, s. 803–816.
- 25 Hallek, M.: Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. *Am J Hematol*, 2015, 90, s. 446–460.
- 26 Jain, P. – Keating, M. – Wierda, W., et al.: Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. *Blood*, 2015, 125, s. 2062–2067.
- 27 Elter, T. – Borchmann, P. – Schulz, H., et al.: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. *J Clin Oncol*, 2005, 23, s. 7024–7031.
- 28 Dighiero, G. – Maloum, K. – Desablens, B., et al.: Chlorambucil in indolent chronic lymphocytic leukemia. *N Engl J Med*, 1998, 338, s. 1506–1514.
- 29 Rai, K. R. – Peterson, P. L. – Appelbaum, F. R., et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. *N Engl J Med*, 2000, 343, s. 1750–1757.
- 30 Brown, J. R. – Hillmen, P. – O'Brien, S., et al.: Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATEM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH 2014, abstrakt 3331. Poster prezentován na 56<sup>th</sup> ASH Annual Meeting and Exposition, 6–9. 12. 2014, San Francisco, CA.